Insider Selling: Vericel (NASDAQ:VCEL) Insider Sells $79,350.00 in Stock

Vericel Corporation (NASDAQ:VCEL) insider Jonathan Siegal sold 1,500 shares of the stock in a transaction on Thursday, November 5th. The shares were sold at an average price of $52.90, for a total value of $79,350.00. Following the completion of the transaction, the insider directly owned 1,259 shares in the company, valued at approximately $66,601.10. This represents a 54.37% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Vericel Price Performance

NASDAQ VCEL opened at $54.62 on Monday. The stock’s 50-day simple moving average is $41.01 and its two-hundred day simple moving average is $38.90. Vericel Corporation has a twelve month low of $28.95 and a twelve month high of $55.60. The company has a market capitalization of $2.80 billion, a price-to-earnings ratio of 85.35 and a beta of 1.08.

Vericel (NASDAQ:VCEL) last posted its quarterly earnings data on Thursday, November 5th. The biotechnology company reported $0.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.06 by $0.21. Vericel had a return on equity of 9.09% and a net margin of 10.27%. The firm had revenue of $85.37 million during the quarter, compared to analysts’ expectations of $77.95 million. During the same period in the prior year, the business earned $0.10 EPS. The company’s revenue for the quarter was up 26.5% compared to the same quarter last year. On average, equities analysts expect that Vericel Corporation will post 0.54 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

VCEL has been the subject of a number of recent research reports. Weiss Ratings restated a “hold (c)” rating on shares of Vericel in a research report on Thursday, October 29th. Truist Financial set a $65.00 target price on Vericel in a research note on Friday. HC Wainwright increased their price target on shares of Vericel from $72.00 to $75.00 and gave the company a “buy” rating in a research report on Friday. TD Cowen lifted their price target on shares of Vericel from $55.00 to $58.00 and gave the stock a “buy” rating in a research note on Friday, July 31st. Finally, Canaccord Genuity Group set a $60.00 price objective on shares of Vericel in a report on Thursday, July 30th. Four analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $60.80.

Institutional Trading of Vericel

Institutional investors have recently added to or reduced their stakes in the business. MCF Advisors LLC increased its stake in Vericel by 293.0% in the 2nd quarter. MCF Advisors LLC now owns 782 shares of the biotechnology company’s stock worth $35,000 after purchasing an additional 583 shares during the period. Ameritas Advisory Services LLC bought a new stake in Vericel in the second quarter valued at approximately $36,000. Allworth Financial LP bought a new stake in Vericel in the second quarter valued at approximately $60,000. Integrated Wealth Concepts LLC purchased a new stake in shares of Vericel during the second quarter valued at approximately $72,000. Finally, GAMMA Investing LLC boosted its stake in shares of Vericel by 17.7% during the second quarter. GAMMA Investing LLC now owns 1,886 shares of the biotechnology company’s stock valued at $84,000 after purchasing an additional 283 shares during the period.

Vericel News Roundup

Here are the key news stories impacting Vericel this week:

• Positive Sentiment: Vericel reported Q3 revenue of $85.4 million, up 26.5% year over year and above the $78.0 million consensus. Earnings per share of $0.27 also topped estimates of $0.06, while net income rose 179% to $14.2 million. Vericel Q3 results and guidance
• Positive Sentiment: The company raised its FY2026 revenue outlook to $344 million–$346 million, above analyst expectations of roughly $336 million, and lifted its adjusted EBITDA margin guidance to 28%. The stronger outlook, alongside record MACI sales, helped fuel investor optimism. Vericel shares rise on record revenue and higher outlook
• Positive Sentiment: HC Wainwright raised its price target to $75 from $72 and maintained a Buy rating, signaling continued analyst confidence in the stock’s prospects. HC Wainwright price target update
• Negative Sentiment: Several Vericel directors and insiders disclosed stock sales totaling about 22,000 shares on November 4–5. One insider’s sale reduced their reported stake by 88%, which may be a near-term concern for investors, though insider sales alone do not establish a negative outlook. SEC insider transaction filing

Vericel Company Profile

Vericel Corporation is a commercial-stage biopharmaceutical company focused on developing and marketing advanced cell therapies and regenerative medicine products. The company serves orthopedic and burn-care markets, with an emphasis on treatments that use a patient’s own cells or biologic materials to support tissue repair and healing.

Vericel’s primary orthopedic product is MACI, an autologous cultured chondrocyte implant used to repair symptomatic cartilage defects of the knee in adults.